Literature DB >> 19669320

Hemodynamic effects of the early and long-term administration of propranolol in rats with intrahepatic portal hypertension.

Lionel Fizanne1, Nicolas Régenet, Jianhua Wang, Frédéric Oberti, Frédéric Moal, Jerôme Roux, Yves Gallois, Sophie Michalak, Paul Calès.   

Abstract

Background and aims The aims of this study were to evaluate a preventive effect on collateral venous circulation of long-term administration of propranolol in intrahepatic portal hypertensive rats. Methods Eighty-six Sprague-Dawley rats were allocated to two models of hepatic fibrosis, bile duct-ligated (BDL) induced and carbon tetrachloride (CCl(4)) induced. Each model was divided into two groups: one receiving placebo and the other propranolol (75 mg kg(-1) d(-1)). Mean arterial pressure (MAP), heart rate (HR), portal pressure (PP), cardiac index (CI), vascular systemic resistance, and splenorenal shunt blood flow (SRS-BF) were measured in anesthetized rats. Results In the BDL model, no significant hemodynamic changes were observed in the propranolol group compared with the placebo group. In CCl(4)-induced rats, HR (390 +/- 50 vs. 329 +/- 51 beats/min, P = .001), CI (44 +/- 11 vs. 34 +/- 10 ml/min, P = .004), PP (15.4 +/- 3.0 vs. 13.4 +/- 1.9 mmHg, P = .045), and SRS-BF (1.4 +/- 1.1 vs. 1.0 +/- 1.0 ml/min, P = .047) were significantly lower in the propranolol group. Conclusions This study showed that propranolol has a significant hemodynamic effect only in the CCl(4) model and suggested a model-dependent effect of propranolol.

Entities:  

Year:  2008        PMID: 19669320      PMCID: PMC2716898          DOI: 10.1007/s12072-008-9070-5

Source DB:  PubMed          Journal:  Hepatol Int        ISSN: 1936-0533            Impact factor:   6.047


  35 in total

1.  A placebo-controlled clinical trial of nadolol in the prophylaxis of growth of small esophageal varices in cirrhosis.

Authors:  Carlo Merkel; Renato Marin; Paolo Angeli; Pierluigi Zanella; Martina Felder; Elisabetta Bernardinello; Giorgio Cavallarin; Massimo Bolognesi; Carlo Donada; Barbara Bellini; Pierluigi Torboli; Angelo Gatta
Journal:  Gastroenterology       Date:  2004-08       Impact factor: 22.682

2.  Prevention of portal hypertension and portosystemic shunts by early chronic administration of clonidine in conscious portal vein-stenosed rats.

Authors:  H C Lin; O Soubrane; D Lebrec
Journal:  Hepatology       Date:  1991-08       Impact factor: 17.425

3.  The porto-systemic collateral pattern in the rat. An angiographic and anatomical study after partial occlusion of the portal vein.

Authors:  J F Halvorsen; A O Myking
Journal:  Eur Surg Res       Date:  1974       Impact factor: 1.745

4.  Prevention of portal hypertension by propranolol and spironolactone in rats with bile duct ligation.

Authors:  F Oberti; H Rifflet; M Y Maïga; C Pilette; Y Gallois; O Douay; J J Le Jeune; J L Saumet; P Calès
Journal:  J Hepatol       Date:  1997-01       Impact factor: 25.083

5.  Lack of effect of propranolol in the prevention of large oesophageal varices in patients with cirrhosis: a randomized trial. French-Speaking Club for the Study of Portal Hypertension.

Authors:  P Calés; F Oberti; J L Payen; S Naveau; D Guyader; P Blanc; A Abergel; P Bichard; J M Raymond; V Canva-Delcambre; D Vetter; D Valla; M Beauchant; A Hadengue; B Champigneulle; J P Pascal; T Poynard; D Lebrec
Journal:  Eur J Gastroenterol Hepatol       Date:  1999-07       Impact factor: 2.566

6.  Desensitization of myocardial beta-adrenergic receptors in cirrhotic rats.

Authors:  S S Lee; J Marty; J Mantz; E Samain; A Braillon; D Lebrec
Journal:  Hepatology       Date:  1990-09       Impact factor: 17.425

7.  Administration of N omega-nitro-L-arginine ameliorates portal-systemic shunting in portal-hypertensive rats.

Authors:  F Y Lee; L A Colombato; A Albillos; R J Groszmann
Journal:  Gastroenterology       Date:  1993-11       Impact factor: 22.682

8.  Propranolol ameliorates the development of portal-systemic shunting in a chronic murine schistosomiasis model of portal hypertension.

Authors:  S K Sarin; R J Groszmann; P G Mosca; M Rojkind; M J Stadecker; R Bhatnagar; A Reuben; Y Dayal
Journal:  J Clin Invest       Date:  1991-03       Impact factor: 14.808

9.  Effect of propranolol on hepatic and systemic hemodynamics in dogs with chronic bile duct ligation.

Authors:  B Willems; J P Villeneuve; P M Huet
Journal:  Hepatology       Date:  1986 Jan-Feb       Impact factor: 17.425

10.  Inhibitory effect of bile on bacterial invasion of enterocytes: possible mechanism for increased translocation associated with obstructive jaundice.

Authors:  C L Wells; R P Jechorek; S L Erlandsen
Journal:  Crit Care Med       Date:  1995-02       Impact factor: 7.598

View more
  4 in total

1.  Pharmacological effects are model specific in animal models of portal hypertension.

Authors:  Flemming Bendtsen; Søren Møller
Journal:  Hepatol Int       Date:  2008-09-03       Impact factor: 6.047

2.  Murine study of portal hypertension associated endothelin-1 hypo-response.

Authors:  Nicholas Theodorakis; Mary Maluccio; Nicholas Skill
Journal:  World J Gastroenterol       Date:  2015-04-28       Impact factor: 5.742

3.  Early primary prophylaxis with beta-blockers does not prevent the growth of small esophageal varices in cirrhosis: a randomized controlled trial.

Authors:  Shiv Kumar Sarin; Smruti Ranjan Mishra; Praveen Sharma; Barjesh Chander Sharma; Ashish Kumar
Journal:  Hepatol Int       Date:  2012-03-10       Impact factor: 6.047

4.  Zolmitriptan: a novel portal hypotensive agent which synergizes with propranolol in lowering portal pressure.

Authors:  Mercedes Reboredo; Haisul C Y Chang; Roberto Barbero; Carlos M Rodríguez-Ortigosa; Francisco Pérez-Vizcaíno; Asunción Morán; Mónica García; Jesús M Banales; Norberto Carreño; Félix Alegre; Ignacio Herrero; Jorge Quiroga; Jesús Prieto; Bruno Sangro
Journal:  PLoS One       Date:  2013-01-16       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.